Wall Street brokerages expect that LeMaitre Vascular Inc (NASDAQ:LMAT) will report earnings per share of $0.21 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular reported earnings per share of $0.43 in the same quarter last year, which would suggest a negative year over year growth rate of 51.2%. The company is expected to report its next earnings report on Thursday, July 25th.
On average, analysts expect that LeMaitre Vascular will report full-year earnings of $0.83 per share for the current financial year, with EPS estimates ranging from $0.82 to $0.84. For the next year, analysts anticipate that the company will post earnings of $0.92 per share, with EPS estimates ranging from $0.89 to $0.95. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 EPS for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). The business had revenue of $28.48 million for the quarter, compared to analysts’ expectations of $27.94 million. LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 earnings per share.
Large investors have recently bought and sold shares of the company. Bank of Montreal Can lifted its position in shares of LeMaitre Vascular by 99.1% in the 4th quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 554 shares during the period. BNP Paribas Arbitrage SA lifted its position in shares of LeMaitre Vascular by 66,640.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 3,337 shares of the medical instruments supplier’s stock worth $103,000 after purchasing an additional 3,332 shares during the period. Municipal Employees Retirement System of Michigan purchased a new stake in shares of LeMaitre Vascular in the 4th quarter worth about $106,000. Metropolitan Life Insurance Co. NY lifted its position in LeMaitre Vascular by 373.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after acquiring an additional 4,441 shares during the period. Finally, Oregon Public Employees Retirement Fund purchased a new position in LeMaitre Vascular during the 4th quarter valued at about $143,000. 77.10% of the stock is owned by hedge funds and other institutional investors.
Shares of LMAT stock opened at $27.26 on Monday. The stock has a market cap of $542.14 million, a PE ratio of 26.25, a P/E/G ratio of 2.77 and a beta of 1.17. The company’s 50 day simple moving average is $26.91. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $38.99.
The business also recently announced a quarterly dividend, which was paid on Thursday, June 6th. Stockholders of record on Wednesday, May 22nd were given a $0.085 dividend. The ex-dividend date was Tuesday, May 21st. This represents a $0.34 annualized dividend and a dividend yield of 1.25%. LeMaitre Vascular’s dividend payout ratio is 40.48%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Read More: Percentage Gainers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.